Background: Obesity is a risk factor for deep vein thrombosis (DVT) and venous thromboembolism (VTE). VTE is the most common cause of mortality in patients undergoing bariatric surgery. There is a remarkable variation in practice regarding methods, dosages and duration of prophylaxis in this patient population. Most of the literature is based on European & American patients and specific guidelines for Egyptians do not exist. Aim of the Work: to compare between obese patients undergoing bariatric surgery who receive Enoxaparin prophylactic dose perioperative and others who receive Rivaroxaban prophylactic dose perioperative, concerning the incidence of development of VTE postoperatively. Patients and Methods: This study was conducted on 40 patients From December 2017 till February 2019. Patients included in the study were essentially attending the Vascular Out-patient Clinic at Ain Shams University Hospitals and Nasser Institute for research & Treatment at Cairo and received postoperative prophylactic doses of Enoxaparin and Rivaroxaban after undergoing bariatric surgeries. Results: This study showed less incidence of DVT in Patients who received Rivaroxaban (5%) than those who received Enoxaparin (10%) but the difference in between the 2 of the was statistically insignificant. In terms of bleeding tendency, both drugs showed no incidence of bleeding tendency. Conclusion: From the previous results, further Randomized Controlled studies should be done on a larger cohort of patients undergoing bariatric surgery to determine the efficacy and to set new guidelines for DVT prophylaxis in bariatric patients bearing in mind terms of efficacy, safety and compliance on therapeutic regimens. Keywords: Rivaroxaban – Enoxaparin - Deep Venous Thrombosis - Pulmonary Embolism.